For Media and Press

Paras Biopharmaceuticals receives Quality Choice award from European Society for Quality Research, Switzerland

Julkaistu 12.12.2016

Paras Biopharmaceuticals is pleased to announce that it has been awarded the Quality Choice Prize 2016 by the European Society for Quality Research (ESQR, Switzerland) on December 12, 2016 in Berlin.

Based on their products and its continuous drive to push the limits of Quality with innovations, Paras Biopharmaceuticals has received the ESQR’s Quality Choice Prize 2016 for their hard work and achievements, in the presence of the international business community for its commitment to quality, excellence and continuous improvement.

On behalf of Paras Biopharmaceuticals, Dr Hans Söderlund, Director: Global Strategy Alliance, received the award during the ceremony held in Berlin. "This award is yet another testament to the good work and dedication of all employees of Paras Biopharmaceuticals”. “It is a continuation of the recognition of Paras Biopharmaceuticals’ operational efforts and performance”.

“Paras Biopharmaceuticals is making its best efforts for developing quality products and efficient technologies for the production of biosimilars in osteoporosis and diabetes" says Dr Ashesh Kumar, CEO & Director: Biologics at Paras Biopharmaceuticals.

The ESQR’s Quality Choice Prize, run by the European Society for Quality Research recognizes the companies, organizations, public administrations with ethics and initiatives that demonstrate exceptional success in quality management and that maximize the full potential of their services through quality-oriented practices. The award takes a comprehensive look at the initiatives and strategies that business leaders implement in their companies and organizations; it recognizes the efforts of exceptional and talented employers and employees and provides motivation for continuous progress.

About Paras Biopharmaceuticals Finland Oy
Based in Oulu, Finland, Paras Biopharmaceuticals is a privately-held Finnish company focused on developing biopharmaceutical manufacturing technologies for biosimilars and long therapeutic peptides. Company’s facilities are dedicated to the development, scale-up and GMP production of recombinant products and high-value recombinant enzymes. The company has successfully developed its Diabrid® Technology Platform for the development of biosimilars in specifically designed expression systems.

About ESQR
The European Society for Quality Research (ESQR) based in Lausanne, Switzerland, handles strategic questions in quality management and promotes Quality Culture and continuous improvement in Quality through the annual Conventions, which serve as a global forum to perfect quality management techniques and provides an excellent networking opportunity for all participants.

Paras Biopharmaceuticals Finland Oy -

Dr Mark Jackson - +358 442905993